not used title
not used title
Earlier this month, the American Cancer Society (ACS) released its annual report, Cancer Statistics 2023, finding the overall cancer mortality rate has declined 33% since peaking in 1991, leading to an estimated 3.8 million averted cancer deaths over this period. The report notes the continued decline in death rates since 1991, including a 1.5% decrease between 2019 and 2020 alone, increasingly reflects advances in prevention and treatment—including new medicines which have improved survival across a range of cancers.
This report is the latest to document this progress. A growing body of evidence underscores the role of new medicines in recent accelerated declines in mortality across a range of cancers. One study found, between 2000 and 2016 alone, new cancer medicines were associated with nearly 1.3 million averted cancer deaths across the 15 most common tumor types. In particular, new cancer medicines were associated with nearly 130,000 prevented breast cancer deaths, nearly 400,000 prevented lung cancer deaths, and over 500,000 prevented melanoma deaths.
While the ACS report highlights tremendous progress in the fight against cancer, it also reveals several alarming trends which threaten this progress and underscores the need for additional efforts to reduce health disparities and address unmet need across a range of cancers.
Here are some key takeaways from the report:
Major reductions in cervical cancer incidence rates among women are tied to administration of the human papillomavirus (HPV) vaccine.
The first vaccine that targets two strains of HPV (HPV-16 and HPV-18) that are responsible for 70% of cervical cancers was approved for females ages nine to 26 by the U.S. Food and Drug Administration (FDA) in 2006. Among women ages 20 to 24 — the first cohort of adolescents to receive the vaccine — the incidence rate of cervical cancer dropped 65% from 2012 to 2019 compared to 33% during the previous seven-year period (2005-2012). The authors note this trend likely foreshadows declines in other HPV-associated cancers in coming years.
Targeted therapies and immunotherapies are improving survival for cancer patients.
For all cancers, the 5-year survival rate was 68% for diagnoses made during 2012 to 2018, up from 49% during the mid-70s. This increase is due in part to improvements in treatment, in particular the development of targeted therapies and immunotherapies, which have transformed the treatment landscape for many different types of cancer.
For example, the report notes patients who were diagnosed with a certain form of leukemia and were treated with tyrosine-kinase inhibitors — a type of targeted therapy — are living near normal life spans. Similarly, a cascade of game changing immunotherapies and targeted therapies have dramatically improved survival for advanced melanoma, leading to a doubling of 3-year survival rates over the past decade and a significant decrease of the number of individuals living with this aggressive form of cancer. Likewise, the report finds overall cancer mortality declines are largely driven by lung cancer, for which mortality declines have steepened in recent years, in part due to treatment advances associated with novel therapies which have extended survival, in addition to earlier detection and other treatments.
Rising incidence of advanced stage cancers which disproportionately impact certain racial groups are particularly concerning.
Cases of prostate, breast and certain types of uterine cancers, all of which are associated with significant disparities in mortality among members of the African American and Black community, are on the rise according to the report. For example, incidence of prostate cancer, the second leading cause of death for men in the U.S., increased by 3% per year between 2014 and 2019 — driven primarily by increased diagnosis of advanced stages of the disease. This trend follows a nearly 2-decade decline, revealing significant gaps in screening and diagnosis which have contributed to this shift, particularly among Black men who face 70% higher incidence of prostate cancer and 2-4 times higher mortality rates relative to every other racial and ethnic group. Successful interventions are needed to reduce these inequalities and continue to accelerate progress against cancer.
To continue to make progress and deliver hope to those battling cancer, the biopharmaceutical industry remains committed to researching and developing innovative medicines that will extend survival and improve the quality of life for cancer patients. Excitingly, there is a robust pipeline of medicines in development targeting various forms of cancer, including breast cancer, ovarian cancer, prostate cancer, pediatric cancer and chronic forms of leukemia and lymphoma. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by the FDA.
While the recent accelerated declines in cancer mortality and the treatment advances that have played a critical role in driving this progress are truly remarkable, significant unmet medical needs and health care inequities persist. Continued progress in the fight against cancer can only be sustained with a policy and regulatory framework that fosters this kind of innovation. That’s why it is concerning that the price setting provision of the Inflation Reduction Act (IRA) severely undercuts biopharmaceutical R&D efforts in a way that runs counter to the fight against cancer. This law will upend incentives for R&D investment, with some economists estimating that the IRA could result in 135 fewer new treatments over the next two decades.
Furthermore, the IRA guts the incentives necessary to encourage investment in R&D after medicines are approved. Post-approval research paves the way for important advancements in patient care that includes expanding and discovering new uses for approved medicines. Some of the most important research on medicines, particularly for disease areas like cancer, happens after a medicine is approved. For example, nearly 60% of oncology medicines approved a decade ago received additional approvals for new indications, and most of those were seven or more years after the initial approval according to an analysis of FDA approval data conducted by Partnership for Health Analytic Research.
In light of the findings of the recent ACS report, it is critical for policymakers to recognize the need for preserving an environment that allows this progress to be sustained. We will continue to educate the public and policymakers about the harm the IRA and other misguided price setting policies will do to patients, R&D and the broader health care system. And we will never stop fighting for the kind of solutions patients and our health care system need.
Read more about the fight against cancer at PhRMA.org/Cancer
Matthew Norawong
Matthew is a senior manager on PhRMA’s Public Affairs team focusing on Medicare, Medicaid, importation and more. Prior to coming to PhRMA, he previously worked as a health policy analyst for National Journal’s Network Science Initiative, primarily supporting companies in the life sciences industry. Matthew completed his undergraduate studies in political science at the University of Washington and subsequently earned a Master of Public Health from the George Washington University. A native of the Pacific Northwest, Matthew currently resides in Washington, DC. Outside of the office, Matthew is an avid runner and enjoys playing bass guitar with his indie rock band.
Matthew Norawong
New study: HPV vaccination helps prevent cervical cancer deaths
July 21, 2026
America's cancer research progress is real and worth protecting
May 28, 2026
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
May 26, 2026
Advancing patient care: A look at new medicines approved in 2025
January 30, 2026
CAREs 2025: Supporting community-based solutions that improve access to medicines
January 22, 2026
New analysis finds 340B hospitals push patients toward costly care to boost profits
January 21, 2026
Price setting policies put cancer gains in jeopardy
January 16, 2026
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
Guest Perspective: Prioritize Innovative Care
February 11, 2025
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
February 3, 2025
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
November 13, 2024
The Patient Perspective: Vaccines
October 23, 2024
The importance of partnership: A conversation with Takeda
October 10, 2024
New Report: Tackling chronic conditions with preventive treatment
September 30, 2024
New Report: Vaccines continue to drive improved health outcomes
July 16, 2024
The future of oncology R&D lies in policymakers’ hands
July 8, 2024
Showcasing the promise of biopharma at ASCO 2024
June 28, 2024
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
May 28, 2024
Critics repeat same, misleading narrative on potential “costs” of new medicines
May 7, 2024
Championing cancer equity: Our drive for healthier AANHPI communities
May 1, 2024
Insurance data: PBM reform has no material impact on premiums
April 24, 2024
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
April 9, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
The impact of innovative medicines: A caregiver's perspective
March 26, 2024
PhRMA awards $250,000 to community-based projects to improve equitable cancer outcomes
February 9, 2024
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
February 7, 2024
Three things to know about antibody drug conjugates
February 2, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
October 18, 2023
Watch: New video series spotlights advances in biopharmaceutical science
August 24, 2023
AARP’s latest misleading report
August 11, 2023
New report: Hospitals mark up medicine prices 500%
August 2, 2023
read more
August 2, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
Between hope and despair: Improving cancer outcomes
July 11, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
June 22, 2023
ASCO 2023: Protecting our progress in the fight against cancer
June 15, 2023
Highlights from ASCO 2023
June 8, 2023
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
May 11, 2023
Insulin: Key Facts on Access & Affordability
May 10, 2023
4 key facts on medicine prices and spending
May 9, 2023
Support for continued progress is critical for pediatric drug development
May 8, 2023
Three facts about health care spending
April 25, 2023
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
March 28, 2023
IRA Impacts: Cancer treatment research and development
March 23, 2023
State policymakers can protect American innovation and help Americans live longer, healthier lives
February 9, 2023
Recognizing National Glaucoma Awareness Month
February 1, 2023
New Report More than 160 medicines in development for mental illness
January 26, 2023
Novel medicines approved in 2022 offer increased treatment options for patients
January 23, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
Study finds hepatitis C cure saved Medicaid $15 billion
January 5, 2023
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
December 1, 2022
New data show how insurers and middlemen shift Rx costs onto patients
November 16, 2022
ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research
November 8, 2022
Protecting treatment advances for breast cancer
October 31, 2022
Busting 3 Myths About Copay Coupons
October 5, 2022
New Report: Nearly 800 medicines in development to treat chronic conditions
September 29, 2022
Recognizing National Sickle Cell Awareness Month
September 23, 2022
Making coupons count for patients at the pharmacy counter
August 25, 2022
By the Numbers: Patients lose when the government sets prices
July 8, 2022
Prescription drug prices are not fueling inflation
July 6, 2022
Key takeaways from ASCO's annual meeting
June 10, 2022
Potential gene therapies bring hope to patients with sickle cell disease
June 6, 2022
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
May 31, 2022
Report finds PBMs are increasingly restricting patient access to medicines
May 25, 2022
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
May 25, 2022
Gene therapies can reduce treatment burden and costs for patients with blood disorders
May 18, 2022
Report: More than 500 medicines in development to treat disorders of the blood
May 18, 2022
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
May 13, 2022
Annual projections from NHE compared to actual health care spending
May 5, 2022
What’s really happening when it comes to prescription drug costs
April 27, 2022
Analysis: States can help patients save nearly $1,000 annually on their medicines
April 21, 2022
New analysis confirms hospitals markup prices for oncology therapies
April 21, 2022
How standardized plans can improve patients’ access to medicines
April 18, 2022
Report: More than 600 medicines in development for diseases affecting women
March 31, 2022
Correcting the record: Putting medicine costs and spending in context
March 24, 2022
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
March 16, 2022
Guest Post: If we truly want to cure complex diseases, politicians should reject price setting
March 14, 2022
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
March 11, 2022
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
March 8, 2022
4 things to know about biopharmaceutical efforts to fight cancer
February 24, 2022
Government price setting leaves behind families counting on new medicines
February 23, 2022
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients
February 8, 2022
Research and development continues long after a medicine is initially approved
February 1, 2022
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
January 25, 2022
CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings
January 21, 2022
New data show continued decline in death rates for cancer patients related to treatment advances
January 20, 2022
New study finds more than half of brand medicine spending goes to the supply chain and others
January 7, 2022
New NHE data show the true picture of health care spending
December 22, 2021
New Report: Nearly 800 new medicines in development to treat rare diseases
December 16, 2021
3 things to know about the importance of post-approval research and development
December 6, 2021
Guest post: Congress should not put future innovation at risk
November 29, 2021
What is missing in the current drug pricing plan
November 23, 2021
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
November 19, 2021
In the current health care debate, Congress has lost sight of what matters to U.S. voters
November 15, 2021
Guest post: Continued research and development is critical for ALS patients and families
October 25, 2021
CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018
October 19, 2021
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
October 18, 2021
New poll shows Americans reject Medicare negotiation once they learn more about the policy
October 15, 2021
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
October 14, 2021
New report shows more than 260 medicines in development to fight neurodegenerative diseases
October 12, 2021
What is Kaiser Family Foundation up to?
October 12, 2021
Recognizing National Immunization Awareness Month
August 31, 2021
Recognizing Hepatitis R&D on World Hepatitis Day
July 28, 2021
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
June 22, 2021
New reports shed light on key facts about medicines and affordability
June 8, 2021
How strengthening the biosimilar marketplace benefits patients
May 18, 2021
New report demonstrates development of new medicines relies on private sector expertise and investment
May 10, 2021
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections
April 29, 2021
West Virginia becomes the first state to lower patient costs by sharing the savings
April 20, 2021
Top five issues voters want addressed in the administration’s first 100 days
February 18, 2021
Action needed to preserve the six protected classes
February 3, 2021
Insurers shift medicine costs to patients with severe chronic illnesses
February 1, 2021
ICYMI: Cancer death rate continues decline due to advances in treatment
January 19, 2021
Report: More than 1,300 medicines and vaccines in development to help fight cancer
December 15, 2020
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
November 19, 2020
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
October 21, 2020
Survey found insurance premiums grew faster than inflation in 2020
October 20, 2020
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
August 19, 2020
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
August 12, 2020
Commercial health plans transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs
August 6, 2020
Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report
August 5, 2020
New data show commercially insured patients face increasingly high cost sharing for brand medicines
July 30, 2020
Payers subject 80% of new RA and MS patients to utilization management restrictions
July 22, 2020
New report explores setbacks that bring future cancer success stories
July 16, 2020
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
June 24, 2020
ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access
June 1, 2020
New rule makes it harder for patients to lower their out-of-pocket costs
May 20, 2020
New report shows nearly 260 vaccines in development, including dozens for COVID-19
April 23, 2020
Nearly 400 cell and gene therapies in development to target a broad range of diseases
March 10, 2020
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
March 3, 2020
Fact Check: HCCI analysis overstates medicine spending and prices
February 19, 2020
Cancer medicines cost twice as much at hospitals, study finds
January 21, 2020
Nearly 50% of brand medicine spending goes to the supply chain and others
January 9, 2020
Nearly 140 medicines in development to treat mental illness
October 10, 2019
More evidence that medicine prices are growing at slowest rate in decades
October 4, 2019
Survey shows out-of-pocket costs top health care concern for voters
October 2, 2019
Four reasons why the radical Pelosi Plan is the wrong approach
September 24, 2019
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
September 10, 2019
Three things to know about the Part D GAO report
August 16, 2019
Setting the record straight on international reference pricing
July 16, 2019
New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?
July 9, 2019
Study finds hospitals continue to mark up medicines up to 500% of their cost
July 9, 2019
Three reasons why the latest Rx Savings Solutions analysis is misleading
July 2, 2019
"If Washington isn’t careful, we might leave innovation behind"
June 24, 2019
Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence
May 15, 2019
New study finds hospitals continue to push patients to costlier outpatient settings
May 13, 2019
4 Things to know about the IQVIA “Medicine Use and Spending” report
May 9, 2019
Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”
May 9, 2019
New report shows more than 160 medicines in development for diabetes and related conditions
April 24, 2019
New report shows nearly 20 innovative medicines in development for sickle cell disease
April 2, 2019
The PBM story you haven’t heard: Hidden fees quadrupled in two years
March 20, 2019
130 medicines in development for asthma, allergies and other respiratory diseases
February 21, 2019
130 medicines in development for asthma, allergies and other respiratory diseases
February 21, 2019
Health Affairs study misses the mark on medicine costs
January 28, 2019
New government data show medicine price growth continues to decline
January 18, 2019
New report shows nearly 300 cell and gene therapies in development
December 6, 2018
World AIDS Day 2018: Hope for the future
December 1, 2018
Americans want to know more than just the list price of a medicine—and we’re answering their call
October 15, 2018
What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising
October 15, 2018
Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles
October 4, 2018
New report shows more than 300 skin disease medicines in development
September 25, 2018
Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program
September 24, 2018
Saving kids and dogs from shared cancers
September 17, 2018
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
September 13, 2018
New report details the setbacks and challenges to Alzheimer’s research
September 12, 2018
New study finds some hospitals mark up medicine prices at least 700 percent
September 5, 2018
69 percent of patients abandon medicines when cost sharing is more than $250
August 23, 2018
New analysis in Health Affairs reinforces one-third of medicine list price rebated back to supply chain
August 13, 2018
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
July 16, 2018
New data show patients’ out-of-pocket costs are rising faster than their insurers’ costs
July 9, 2018
Medicare Part D cliff ahead
June 21, 2018
Part D cliff looms for seniors, as program stability could be in jeopardy
June 18, 2018
New analysis shows that more medicines worldwide are available to U.S. patients
June 5, 2018
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
June 1, 2018
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
May 30, 2018
Sharing negotiated discounts at the pharmacy counter could save seniors with diabetes more than $350 annually
May 17, 2018
New “Let’s Talk About Medicare” campaign focuses on solutions to improve affordability and predictability for seniors in Part D
May 9, 2018
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
May 4, 2018
Event tomorrow: Making the biopharmaceutical supply chain work for patients
May 2, 2018
A new era in Alzheimer’s innovation
April 19, 2018
Spending on medicines grew less than one percent in 2017
April 19, 2018
New report shows over 500 medicines in development for neurological disorders
April 18, 2018
Patients pay the price when hospitals mark up cancer medicines
April 5, 2018
Advance price notification: A transparency measure that fails patients
March 29, 2018
New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed
March 27, 2018
Video: How does the supply chain shape brand-name medicine prices?
March 19, 2018
4 Things to know about the IQVIA 2018 and Beyond: Outlook and Turning Points report
March 13, 2018
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
March 2, 2018
Guest post: Advancing healthy hearts for patients
February 28, 2018
New report shows 200 medicines in development for heart disease and stroke
February 20, 2018
Copay coupons can help ease patients’ out-of-pocket costs
February 16, 2018
Oregon’s HB 4005 fails to deliver savings for patients
February 14, 2018
PhRMA launches new consumer-facing Let’s Talk About Cost website
January 24, 2018